Non-small-cell lung cancer

LEL Hendriks, J Remon, C Faivre-Finn… - Nature Reviews …, 2024 - nature.com
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is
responsible for the majority of cancer-related deaths worldwide. The management of …

TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling

WT Lu, LP Zalmas, C Bailey, JRM Black… - Nature Cell …, 2024 - nature.com
Chromosomal instability (CIN) is common in solid tumours and fuels evolutionary adaptation
and poor prognosis by increasing intratumour heterogeneity. Systematic characterization of …

Artificial intelligence-based biomarkers for treatment decisions in oncology

M Ligero, OSM El Nahhas, M Aldea, JN Kather - Trends in Cancer, 2025 - cell.com
The development of new therapeutic strategies such as immune checkpoint inhibitors (ICIs)
and targeted therapies has increased the complexity of the treatment landscape for solid …

Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer

A McPherson, I Vázquez-García, MA Myers, M Zatzman… - bioRxiv, 2024 - biorxiv.org
Whole-genome doubling (WGD) is a critical driver of tumor development and is linked to
drug resistance and metastasis in solid malignancies. Here, we demonstrate that WGD is an …

EGFR, TP53, and CUL3 Triple Mutation in Non‐Small Cell Lung Cancer and its Potentially Poor Prognosis: A Case Report and Database Analysis

H Hatano, T Yoshida, R Higashiyama… - Thoracic …, 2024 - Wiley Online Library
Concurrent mutations in tumor protein p53 (TP53) or Kelch‐like ECH‐associated protein 1‐
nuclear factor erythroid 2‐related factor 2‐pathway components are linked to poor outcomes …

[HTML][HTML] Concurrent TP53 mutations facilitate resistance evolution in EGFR exon 20 S768I mutant lung adenocarcinoma: a case report and review of the literature

H Zhu, H Tang, H Peng, W Ding - Case Reports in Oncology, 2025 - karger.com
Introduction: Adenocarcinoma of the lung is the most common subtype of non-small cell lung
cancer, and epidermal growth factor receptor (EGFR) mutations are the most common driver …

Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using In Silico Modelling

MA Clarke, CG Barker, A Nicholls, MP Handler… - bioRxiv, 2025 - biorxiv.org
The disease burden from non-small cell lung cancer (NSCLC) adenocarcinoma is
substantial, with around a million new cases diagnosed globally each year, and a 5-year …

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers

AAN Rose, JL Maxwell, E Rousselle, M Riaud… - medRxiv, 2024 - medrxiv.org
Class 2 and 3 non-V600E BRAF mutations are oncogenic drivers in many cancer types.
Currently, there are no established targeted therapies with proven efficacy for cancers with …

Tobacco smoke alters the landscape of mutation, selection, and epistasis in lung adenocarcinoma

K Dasari, JA Alfaro-Murillo, JP Townsend - bioRxiv, 2024 - biorxiv.org
Tobacco smoke elevates mutagenesis. Its physiological effects may additionally influence
the adaptive benefits of specific mutations to oncogenesis. However, the relative …

contribute to chromosomal instability in cancer cells

WT Lu, N Kanu - nature.com
FAT1 alterations contribute to chromosomal instability in cancer cells | Nature Cell Biology Skip
to main content Thank you for visiting nature.com. You are using a browser version with limited …